Simplify Logo

Full-Time

Organ Health Specialist

Posted on 7/22/2024

Natera

Natera

1,001-5,000 employees

Biotechnology firm specializing in genetic testing

Hardware
Biotechnology
Healthcare

Compensation Overview

$115k - $140kAnnually

+ Commission

Senior, Expert

Vermont, USA + 4 more

Category
Field Sales
Sales & Account Management
Required Skills
Sales
Requirements
  • Bachelor's Degree or equivalent educational background
  • Minimum of 6 years of progressive sales experience in the diagnostic or lab-developed tests industry
  • Knowledge of academic medical systems related to transplant, nephrology, or specialty medicine
  • Established relationships with KOLs in transplant or specialty medicine
  • Background in medicine, biological sciences, or genetics is preferred
Responsibilities
  • Exceeding performance goals and establishing client relationships in the transplant market
  • Closing sales, fostering client relationships, and driving sustainable growth
  • Launching products in the transplant market and contributing to brand development
  • Becoming a local expert on Natera’s technology and services
  • Developing and executing local business plans to meet sales objectives

Natera focuses on genetic testing and diagnostics, providing advanced solutions for cancer patients, transplant patients, and individuals assessing hereditary health risks. Their main technology, cell-free DNA (cfDNA) testing, analyzes DNA fragments in the blood to detect minimal traces of cancer and assess organ health. Natera stands out by offering specialized tests like the Signatera ctDNA test and Panorama NIPT, along with genetic counseling services. The company's goal is to improve patient care through accurate genetic insights and early detection of health issues.

Company Stage

IPO

Total Funding

$1.2B

Headquarters

Austin, Texas

Founded

2004

Growth & Insights
Headcount

6 month growth

8%

1 year growth

20%

2 year growth

52%
Simplify Jobs

Simplify's Take

What believers are saying

  • Natera's continuous innovation, such as the launch of the Prospera Heart test with DQS, demonstrates its commitment to improving patient outcomes and maintaining market leadership.
  • The company's diverse product offerings across oncology, transplant health, and women's health provide multiple revenue streams and reduce dependency on a single market.
  • Significant investments from entities like Massachusetts Financial Services Co. MA indicate strong financial backing and confidence in Natera's growth potential.

What critics are saying

  • Allegations of deceptive sales and billing practices could damage Natera's reputation and lead to legal and financial repercussions.
  • The highly competitive nature of the genetic testing market requires constant innovation and differentiation to maintain market share.

What makes Natera unique

  • Natera's focus on cell-free DNA (cfDNA) technology for a wide range of applications, from oncology to prenatal screening, sets it apart from competitors who may specialize in only one area.
  • The introduction of unique features like the Donor Quantity Score (DQS) for transplant rejection detection enhances the accuracy and reliability of their tests, distinguishing them from other genetic testing companies.
  • Natera's extensive portfolio of over 200 peer-reviewed publications underscores its commitment to scientific validation and credibility, which is a significant competitive advantage.

Benefits

Flexible medical plans

Investment options

Time off

Workplace perks

INACTIVE